Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: a SWOG and Blood & Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).

•A phase II tandem AHSCT trial in relapsed/refractory Hodgkin lymphoma was performed.•Eighty-nine eligible patients were treated; 47 (53%) had primary refractory HL.•There were no treatment-related deaths in the first year after AHSCT.•With a median follow-up of 6.2 years, 2-year and 5-year PFS were 63% and 55%.•Tandem AHSCT may overcome the negative prognostic impact of primary refractory disease